Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T21408 |
DM1-SMe
DM1-SSMe |
Microtubule Associated | Cytoskeletal Signaling |
DM1-SMe (DM1-SSMe) 是美登木素微管的有效抑制剂。 DM1-SMe 的效力是母体药物美登素的 3 至 10 倍,在一组人类肿瘤细胞系中,DM1-SMe 的 IC50 为 0.003 至 0.01 nM。 | |||
T16899 |
SMCC-DM1
DM1-SMCC |
Others | Others |
SMCC-DM1 (DM1-SMCC) 是一种药物-接头偶联物,由有效的微管破坏剂 DM1 和接头 SMCC 组成,用于制备抗体药物偶联物。 | |||
T11917 |
Lys-SMCC-DM1
Lys-Nε-MCC-DM1 |
Microtubule Associated | Cytoskeletal Signaling |
DM1 是一种微管蛋白抑制剂。 Lys-SMCC-DM1 (Lys-Nε-MCC-DM1) 是 DM1 的活性代谢物。 | |||
T1992 |
Mertansine
DM1,Maytansinoid DM1 |
Microtubule Associated | Cytoskeletal Signaling |
Mertansine (DM1) 是一种微管蛋白抑制剂,也是一种抗体可缀合的美登木素生物碱。它通过连接体连接到单克隆抗体上,形成抗体偶联药物。 | |||
T24007 |
DM1-MCC
MCC-DM1 |
Others | Others |
DM1-MCC (MCC-DM1) 是一种具有 MCC 接头的抗癌药物 DM1。 | |||
T38493 |
MCC-DM1
MCC-DM1 |
||
MCC-DM1 is a drug-Linker Conjugates for ADC such ad Anti-CD22-MCC-DM1. | |||
T38788 |
MC-DM1
MC-DM1 |
||
MC-DM1 is a drug-linker conjugate composed of a potent microtubule-disrupting agent DM1 and a linker MC to make antibody drug conjugate (ADC). | |||
T18718 |
SPP-DM1
|
Others | Others |
SPP-DM1, a drug-linker conjugate for antibody-drug conjugates (ADC), demonstrates potent antitumor activity. It comprises DM1 (a potent microtubule-disrupting agent) connected through the ADC linker SPP[1]. | |||
T12805 |
S-methyl DM1
|
Microtubule Associated | Cytoskeletal Signaling |
S-methyl DM1 is a thiomethyl derivative of Maytansine. S-methyl DM1 binds to tubulin(Kd of 0.93 μM) and inhibts microtubule polymerization. | |||
T17832 |
DM1-PEG4-DBCO
|
Others | Others |
DM1-(PEG)4-DBCO is a drug-linker conjugate that combines the potent microtubulin inhibitor mertansine (DM1) with the DBCO-PEG4-Ahx linker for the development of antibody-drug conjugates (ADCs). This conjugation aims to mitigate the systemic toxicity associated with maytansine while improving tumor-specific delivery, leveraging DM1’s capabilities as an antibody-conjugatable maytansinoid. | |||
T18305 |
Mal-VC-PAB-DM1
|
Others | Others |
Mal-VC-PAB-DM1, a drug-linker conjugate for antibody-drug conjugates (ADCs), exhibits potent antitumor activity. It incorporates DM1, a potent microtubule-disrupting agent, connected through the ADC linker Mal-VC-PAB [1]. | |||
T17793 |
DBCO-PEG4-Ahx-DM1
|
Others | Others |
DBCO-PEG4-Ahx-DM1 is a drug-linker conjugate that combines the microtubulin inhibitor DM1 (mertansine), which is an antibody-conjugatable maytansinoid designed to reduce systemic toxicity and improve tumor-specific delivery, with the linker DBCO-PEG4-Ahx, for the development of antibody drug conjugates (ADCs). | |||
T18678 |
SC-VC-PAB-DM1
|
Others | Others |
SC-VC-PAB-DM1 is a drug-linker conjugate utilized in Antibody-Drug Conjugates (ADC), featuring DM1 (Mertansine, a tubulin inhibitor) linked through the SC-VC-PAB[1] ADC linker to deliver potent antitumor activity. | |||
T77848 |
vc-PABC-DM1
|
||
vc-PABC-DM1用于合成基于二硫键的ADC分子,且可探索其血清稳定性。 | |||
T5541 |
PDM11
1-[2-(4-Chloro-phenyl)-vinyl]-3,5-diMeth,PDM 11 |
AhR | Immunology/Inflammation; Metabolism |
PDM11 (1-[2-(4-Chloro-phenyl)-vinyl]-3,5-diMeth) 是抗氧化剂白藜芦醇的衍生物。它在白藜芦醇活性测定中不活跃。它对辐射分解产生的羟基自由基引发的亚油酸胶束氧化没有明显的保护作用。 | |||
T28235 |
OMDM169
OMDM 169,OMDM-169 |
||
OMDM169 is a potent and selective MAGL inhibitor. OMDM169 could enhances 2-AG levels and of exerts analgesic activity via indirect activation of cannabinoid receptors. OMDM169 exhibited 0.13 microM<IC(50)<0.41 microM towards 2-AG hydrolysing activities in | |||
T25141 |
BDM14471
BDM-14471,BDM 14471 |
||
BDM14471 is a selective inhibitor of hydroxamate PfAM1. | |||
T62405 | KDM1/CDK1-IN-1 | ||
KDM1/CDK1-IN-1 (compound 4) 是一种有效的 KDM1 (IC50: 0.096 μM) 和 CDK1 (IC50: 0.078 μM) 抑制剂。KDM1/CDK1-IN-1 能够将 HOP-92 细胞的细胞周期阻滞在 G2/M 期,并诱导其凋亡 (apoptosis)。KDM1/CDK1-IN-1 对 CCRF-CEM 细胞 (IC50: 16.34 μM)、HOP-92 细胞 (IC50: 3.45 μM) 和 Hep-G2 细胞 (IC50: 7.79 μM) 具有较强的细胞毒性。 | |||
T80721 | Zndm19 | ||
Zndm19为New Delhi Metallo-β-lactamase-1 (NDM-1)的抑制剂,适用于抗药性细菌感染研究。 | |||
T68612 |
DM175
|
||
DM175 is a novel partial FXR agonist, causing specific modulatory effects on FXR activity that clearly differ from classical FXR agonists. | |||
T24647 |
PKR-IN-C51
PKRINC51,PKR IN C51,PKR-inhibitor-C51,PKR inhibitor C51 |
||
PKR-IN-C51 is an inhibitor of protein kinase R. It acts by correcting the aberrant splicing of MBNL1-dependent pre-mRNAs in DM1 cells without affecting the splicing pattern in normal non-DM1 cells. | |||
T76939 | Cantuzumab mertansine | ||
Cantuzumab mertansine (SB-408075; huC242-DM1) 是一种ADC,是强效美登素衍生物 (DM1) 和针对 CanAg 的人源化单克隆抗体 (huC242) 的免疫偶联物。Cantuzumab mertansine 对结肠癌细胞具有细胞毒性,并且对一系列 CanAg 阳性人肿瘤异种移植物具有广泛的抗肿瘤活性。 | |||
T36647 | Trastuzumab emtansine | Others | Others |
Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that combines the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of DM1, a microtubule-inhibitory derivative of maytansine. This compound is utilized in the investigation of advanced breast cancer[1][2]. | |||
T77821 |
MCC
|
||
MCC 为一种用于ADC合成的不可降解连接子,例如用于制得MCC-DM1。 | |||
T18702 |
DBA-DM4
|
Others | Others |
DBA-DM4 is a drug-linker conjugate for antibody-drug conjugate (ADC) synthesis, combining the tubulin inhibitor DM1 with the SPDP linker[1]. | |||
TP1804 |
PEN-221
|
||
PEN-221 is a Somatostatin receptor 2 (SSTR2)-targeting cytotoxic conjugate with an IC50 of 10 nM. PEN-221 is a conjugate consisting of microtubule-targeting agent DM1 linked to the C-terminal side chain of Tyr3-octreotate. |